Since our launch at CES earlier this year,we’ve attracted support from major industry backers (to the sum of £3 million so far) such
as Innovate UK, DSTL (the science and technology provider to MOD) and Bodytrak’s major stakeholder, Breed Reply - part of the €780 million Reply Group (2016 revenue).
Matthew Scherba, Partner at Breed Reply recently talked of why his company is following investment in the current round; “Bodytrak is an exciting IoT-based company, with a clear technological lead with their non-invasive, gold-standard, in-ear physiological monitoring solution. Their combination of unique hardware and recurring platform revenue is able to service compelling cross-sector applications in health, wellness and health and safety, with significant early traction already gained in each of these markets. These, along with the development of the management team, and our belief in their ability to execute, are the key reasons Breed Reply is re-investing in Bodytrak.”
“We invested because of the potential we saw in the physiological monitoring, and specifically the core body temperature, which no-one else had, which was of gold standard and had been gold standard tested by Loughborough University, and they have a strengthening IP portfolio, potential going forward as well.
The current round allows the company to really scale Bodytrak into the market. They have some significant partners they are speaking to, they are conducting over 40 trials in key market sectors of emergency services, health and safety and sports, and have some really good early traction to scale this product into the market.”
To find out more about investing in Bodytrak, get in touch with CEO Leon Marsh @ email@example.com